Heat Biologics, Inc. (NASDAQ:HTBX) Files An 8-K Results of Operations and Financial Condition

Heat Biologics, Inc. (NASDAQ:HTBX) Files An 8-K Results of Operations and Financial Condition
Item 2.02Results of Operations and Financial Condition.

Story continues below

On March 28, 2019, Heat Biologics, Inc., a Delaware corporation (the “Registrant”), issued the attached press release that included financial information for its fiscal year ended December 31, 2018. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in the press release is being furnished to the Securities and Exchange Commission (the “Commission”) and shall not be deemed incorporated by reference into any of the Registrant’s registration statements or other filings with the Commission.

Item 9.01Financial Statements and Exhibits.

HEAT BIOLOGICS, INC. Exhibit
EX-99.1 2 htbx_ex99z1.htm PRESS RELEASE Press Release   EXHIBIT 99.1 Heat Biologics Reports 2018 Results and Provides Corporate Update Recently announced interim HS-110 Phase 2 data demonstrating survival benefit in patients with ‘cold’ tumors (CD8+ TILs < 10% at baseline) who are least likely to respond to checkpoint inhibitors alone Preliminary data suggests the addition of HS-110 to Bristol-Myers Squibb’s anti-PD-1 checkpoint inhibitor Opdivo® (nivolumab) may restore responsiveness to treatment after tumor progression on prior checkpoint inhibitor therapy Company remains on track to complete enrollment of Phase 2 lung cancer trial in Q2 2019 and report additional interim data in Q4 2019 Fully funded through completion of HS-110 Phase 2 trial with approximately $28 million of cash and investments at year end plus an additional $6.9 million in grant funds expected in Q2 2019 DURHAM,…
To view the full exhibit click here

About Heat Biologics, Inc. (NASDAQ:HTBX)

Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.

An ad to help with our costs